Detailed narrative
MYQORZO U.S. Commercial Launch Exceeds Expectations
Cytokinetics reported a strong initial U.S. launch for MYQORZO, its first approved medicine for symptomatic oHCM, generating $4.8 million in net product revenue in a partial first quarter. The launch saw rapid HCP prescribing, with over 275 unique HCPs prescribing MYQORZO by Q1 end and increasing to 425 by April. The company observed high engagement from prescribers, with over 1,400 HCPs becoming REMS certified, and a new-to-brand Q1 exit share estimated to be greater than 30% among high-volume CMI writers.
Aficamten's ACACIA-HCM Trial Meets Primary Endpoints in nHCM
The pivotal Phase III ACACIA-HCM trial for aficamten in nonobstructive HCM met both dual primary endpoints, demonstrating statistically significant improvements in KCCQ clinical summary score (11.4 points vs. 8.4 points for placebo, p=0.021) and peak VO2 (0.64 ml/kg/min vs. 0.03 ml/kg/min for placebo, p=0.003). These results suggest aficamten could be the first approved therapy for nHCM, potentially treating the full spectrum of HCM. No new safety signals were identified, with LVEF less than 50% occurring in 10% of aficamten patients and 1% of placebo patients.
Global Expansion and Regulatory Progress for MYQORZO and Aficamten
Beyond the U.S., MYQORZO received European Commission approval, with the first European launch planned for Germany in Q2 FY26. The company has submitted 6 HTA dossiers across the EU and expects 5 more this quarter. For aficamten, the sNDA for MAPLE-HCM was accepted by the FDA with a PDUFA date of November 14, 2026. An MAA was submitted in Switzerland, and a decision is expected in Canada in 2H 2026. Aficamten also received orphan drug designation in Japan for both nHCM and pediatric oHCM.
Pipeline Advancement in HCM and Heart Failure
Cytokinetics continues to advance its clinical pipeline. In HCM, CAMELLIA-HCM (aficamten in Japanese oHCM) and CEDAR-HCM (aficamten in pediatric oHCM) are progressing, with CEDAR-HCM adolescent cohort enrollment expected to complete by year-end. In heart failure, COMET-HF (omecamtiv mecarbil in HFrEF) is enrolling patients, and AMBER-HFpEF (ulacamten in HFpEF) is expanding enrollment in Cohort 1, expected to complete in 2H 2026. A second Phase I study for CK-089 is also planned for FY26.
Financial Overview and Capital Allocation
Total revenues for Q1 FY26 were $19.4 million, up from $1.6 million in Q1 FY25, driven by $4.8 million in MYQORZO net product revenue and an $11.9 million milestone from Bayer. R&D expenses decreased slightly to $95.5 million, while SG&A increased to $104.9 million due to MYQORZO commercial launch activities. The net loss was $206 million. The company ended the quarter with $1.1 billion in cash and investments and maintained its full-year GAAP combined R&D and SG&A expense guidance of $830 million to $870 million.